

Dear SASCRO Colleagues,

A request was made by a medical scheme to SASCRO on 14 January 2019 for comments on the role of SBRT for oligo-metastatic prostate cancer.

The response is filed as a statement on the SASCRO website:

<http://sascro.org/2019/02/13/sascro-statement-on-sbrt-for-oligo-metastatic-prostate-cancer/>

The response was co-authored by Greg Hart, David Anderson, Wilhelm van Zijl and myself on behalf of the SASCRO Committee.

SASCRO does not get involved in the details of patient selection and restricts comments to general principles.

Kind Regards,
Raymond Abratt
SASCRO Chair

